title: SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
abstract: BACKGROUND
  Gene SLCO1B1, encoding solute organic anionic transport polypeptide OATP1B1, belongs to the group of candidates potentially influencing statin treatment safety. OATP1B1 regulates (not only) the hepatic uptake of statins. Its genetic variation was described as an important predictor of statin-associated myopathy in a cohort of patients treated with a maximum dose of simvastatin. However, the impact of SLCO1B1 gene polymorphism on this risk in patients treated with other statins or lower doses of simvastatin needs to be assessed. Therefore, we performed the present study.
  
  
  METHODS
  SLCO1B1 tagging rs4363657 polymorphism was analyzed in 2 groups of patients with dyslipidemia (treated with simvastatin or atorvastatin, 10 or 20 mg per day), subgroup with statin-induced myalgia (N=286), and subgroup (N=707) without myalgia/myopathy, and in 2301 population controls without lipid-lowering treatment.
  
  
  RESULTS
  Frequency of the individual genotypes in patients with myalgia/myopathy (TT=62.3%, CT=34.5%, CC=2.8%) did not significantly differ (both P values over 0.19) from that in patients without muscle symptoms (TT=61.4%, CT=32.9%, CC=5.7%) or from the population controls (TT=63.9%, CT=32.5%, CC=3.6%). Null results were also obtained for the dominant and recessive models of the analysis.
  
  
  CONCLUSIONS
  In Czech patients treated with low statin doses, there is no association between SLCO1B1 gene polymorphism and risk of myalgia/myopathy.
authors.affiliation: Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
authors.forename: Jaroslav A
authors.initials: JA
authors.lastname: Hubáček
authors.affiliation: Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
authors.forename: Dana
authors.initials: D
authors.lastname: Dlouhá
authors.affiliation: Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
authors.forename: Vera
authors.initials: V
authors.lastname: Adámková
authors.affiliation: 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University Prague, Prague, Czech Republic.
authors.forename: Lukáš
authors.initials: L
authors.lastname: Zlatohlavek
authors.affiliation: Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
authors.forename: Ondřej
authors.initials: O
authors.lastname: Viklický
authors.affiliation: Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
authors.forename: Petra
authors.initials: P
authors.lastname: Hrubá
authors.affiliation: 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University Prague, Prague, Czech Republic.
authors.forename: Richard
authors.initials: R
authors.lastname: Češka
authors.affiliation: 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University Prague, Prague, Czech Republic.
authors.forename: Michal
authors.initials: M
authors.lastname: Vrablík
mesh_terms: D000368:Aged; D000069059:Atorvastatin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D018153:Czech Republic / Q000453:epidemiology; D003920:Diabetes Mellitus / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D050171:Dyslipidemias / Q000188:drug therapy / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D027381:Liver-Specific Organic Anion Transporter 1; D008297:Male; D008875:Middle Aged; D008957:Models, Genetic; D009135:Muscular Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics; D063806:Myalgia / Q000139:chemically induced / Q000453:epidemiology / Q000235:genetics; D009765:Obesity / Q000453:epidemiology; D027361:Organic Anion Transporters / Q000235:genetics* / Q000502:physiology; D020641:Polymorphism, Single Nucleotide; D019821:Simvastatin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D012907:Smoking / Q000453:epidemiology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D027381:Liver-Specific Organic Anion Transporter 1; D027361:Organic Anion Transporters; C503999:SLCO1B1 protein, human; D000069059:Atorvastatin; D019821:Simvastatin